Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Chiasma Inc (NASDAQ: CHMA) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Chiasma Inc (NASDAQ: CHMA) concerning whether a series of statements by Chiasma Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

In July of 2015, Chiasma offered shares at $16.00 per share in its IPO. On April 15, 2016, Chiasma Inc revealed the receipt of a Complete Response Letter from the U.S. Food and Drug Administration, indicating that Chiasma’s New Drug Application for Mycapssa (octreotide) capsules was not yet ready for approval in its present form.

Following this news, NASDAQ: CHMA dropped 63.13% on April 18, 2016.

Based in Newton, Massachusetts, and founded in 2001 Chiasma Inc focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases.

If you purchased shares of Chiasma Inc (NASDAQ: CHMA) you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185